Overview

Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the absolute oral bioavailability of dapagliflozin.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Bristol-Myers Squibb
Treatments:
Dapagliflozin